Cytotoxic and proliferative effects of novel compounds are screened on mammalian cell lines. > 100 cell lines are available for screening. Due to their pivotal role in drug metabolism, all compounds are tested on permanent human hepatocytes.
For the prediction of bioavailability in animal models, compounds are tested on an epithelial cell-derived transport model. The applied mammalian cells are human colorectal adenocarcinoma cell line, CaCo-2. Analysis is performed by LC-MS. The apparent permeability coefficient (Papp) is used to estimate bioavailability.
The Molecular Biotechnology Unit has a longstanding expertise in experimental research using primary cells of the central nervous system.
For the prediction of bioavailability in animal models, compounds are tested on an epithelial cell-derived transport model. The applied mammalian cells are human colorectal adenocarcinoma cell line, CaCo-2. Analysis is performed by LC-MS. The apparent permeability coefficient (Papp) is used to estimate bioavailability.
Phenotyping of transgenic mouse models follows the SHIRPA protocol. It is divided into primary, secondary and tertiary screen. Comprehensive test batteries for evaluating animal health and specific functions, e.g. motor coordination, cognition and emotion are available. Focus is on automated home cage observation to minimize the contact of humans with the laboratory mice.
The determination of pharmacological parameters, e.g. bioavailability and plasma half-life, is done in-house using catheterized rats. Experiments are performed after extensive testing of compounds in isolated cell cultures and after allowance by the local animal well-fare committee. For measuring compound levels in body fluids, LC-MS-based methods are available.